System, kit and amplification method for efficiently amplifying NK (Natural Killer) cells, cells for amplification and application of cells

By expressing OX40L on the feeder cell surface and constructing the K562-OX40L cell line, the problems of unknown mechanism of NK cell amplification and limited effect of OX40L in the prior art were solved, and efficient NK cell amplification and activation were achieved, with a significant expansion fold. Improvement, ADCC toxicity and molecular marker expression have been improved.

CN118995598APending Publication Date: 2024-11-22SUZHOU INDAL PARK HUMAN ANTIBODOMICS DEV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310568764.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-19
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

In the prior art, the mechanism of NK cell amplification has not been clarified through the interaction between engineered feeder cells expressing costimulators and NK cells, and the soluble OX40L has limited role in the NK amplification system, making it difficult to effectively stimulate NK. Cell expansion.

Method used

Genetically engineered methods were used to express OX40L on the feeder cell surface, and overexpression of OX40L was achieved by constructing the K562-OX40L cell line, and used to co-culture with NK cells to promote their amplification.

Benefits of technology

The amplification efficiency of NK cells was significantly improved, with a 5-10-fold increase in the expansion fold. The prepared NK cells were similar to those of traditional methods in ADCC, and the abundance of surface molecular markers was higher than that of natural NK cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995598A_ABST
    Figure CN118995598A_ABST
Patent Text Reader

Abstract

The invention provides a system for amplifying NK (Natural Killer) cells. The system comprises OX40L, and / or co-culture of cells expressing the OX40L and the NK cells. The invention further provides a kit for amplifying the NK cells, an amplification method and application of the system, the kit and the amplification method. According to the invention, the OX40L is used as a novel co-stimulating factor for promoting the amplification of the human NK cells for the first time, and the OX40L and / or cells expressing the OX40L and the NK cells are co-cultured, so that the NK cells are efficiently amplified.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of cancer treatment, and in particular relates to a system, a kit, an amplification method, cells for amplification and applications thereof for efficiently amplifying NK cells. Background Art

[0002] Adoptive transfer of natural killer (NK) cells is a promising adjuvant approach for cancer immunotherapy, so obtaining a sufficient number of activated NK cells is important for effective NK cell-based immunotherapy. The mechanism of NK cell expansion has not been fully elucidated, and there is some blindness and randomness in the interaction between engineered feeder cells expressing co-stimulatory factors and NK cells. Several soluble cytokines (such as IL-2 and IL-15) have been used to expand NK cells, but the use of IL-2 alone or in combination with IL-15 is less efficient for NK cell expansion.

[0003] Other cofactors or stimulators (i.e., feeder cells) can greatly enhance the in vitro expansion of NK cells. When K562 cells and IL-2 are used together, the expansion of NK cells is higher than when IL-2 is used alone. Recently, the use of engineered K562 cells to express cytokines and co-stimulatory factors, such as membrane-bound (mb) IL-15, mbIL-21, and 4-1BB ligand, has achieved significant activation and expansion of NK cells. Although 4-1BB ligand has been shown to be a key factor, the field is still searching for other novel co-stimulatory factors for NK cell activation and expansion. In addition, the mechanism of NK cell expansion through the interaction between engineered feeder cells expressing co-stimulatory factors and NK cells has not been elucidated. Recent studies have found that the expansion of NK cells, the production of IFN-γ in NK cells, and the killing activity of NK cells can be stimulated through the OX40 receptor (OX40L).

[0004] However, the effect of soluble OX40L in the NK expansion system is still very limited. Therefore, how to use OX40L to stimulate the expansion of NK cells is an urgent problem to be solved in the existing technology. Summary of the invention

[0005] In view of the above-mentioned shortcomings of the prior art, the object of the present invention is to provide the use of OX40L as a new co-stimulatory factor for promoting the expansion of human NK cells, so as to solve the problems in the prior art.

[0006] To achieve the above-mentioned purpose and other related purposes, the present invention provides a system for amplifying NK cells, the system comprising OX40L and / or cells expressing OX40L. Optionally, the system also comprises NK cells co-cultured with OX40L and / or cells expressing OX40L. By adopting a genetic engineering method to express OX40L on the surface of feeder cells, great application potential is exerted in NK cell amplification and large-scale production preparation.

[0007] Natural killer cells (NK) are important immune cells in the body. They are not only related to anti-tumor, anti-viral infection and immune regulation, but also participate in the occurrence of hypersensitivity reactions and autoimmune diseases in some cases. They can recognize target cells and killing mediators. They are derived from bone marrow lymphoid stem cells. Their differentiation and development depend on the bone marrow and thymus microenvironment. They are mainly distributed in the bone marrow, peripheral blood, liver, spleen, lungs and lymph nodes. They are a type of lymphocytes that can non-specifically kill tumor cells and virus-infected cells without prior sensitization. NK cells have some T cell differentiation antigens, and NK cells have IL-2 affinity receptors. They can proliferate under IL-2 stimulation, and activated NK cells can produce IFN-γ. Therefore, it is generally believed that NK cells and T cells are more closely related in development.

[0008] OX40L is the ligand of OX40. They are a pair of important co-stimulatory molecules in the body's immune response process, participating in the activation, proliferation and migration of T cells, the formation of germinal centers and the differentiation and maturation of dendritic cells. They play an important role in mediating tumor immune responses and the occurrence and development of autoimmune diseases.

[0009] As certain embodiments of the present invention, the amino acid sequence of OX40L is as shown in SEQ ID No. 1; and the positive rate of OX40L expression on the cell surface of the cells expressing OX40L is greater than 90%.

[0010] As certain embodiments of the present invention, the cell expressing OX40L is a K562 cell expressing OX40L, K562-OX40L.

[0011] K562 cells are the first artificially cultured human myeloid leukemia cells. The type of erythroleukemia K562 cells is lymphoblastoid cells derived from female patients in the blast phase of chronic myeloid leukemia and is used to study tumor and leukemia treatment, drug targets and other fields.

[0012] The present invention also provides a kit for expanding NK cells, wherein the kit comprises OX40L and / or cells expressing OX40L.

[0013] As certain embodiments of the present invention, the amino acid sequence of OX40L is shown in SEQ ID No. 1; the positive rate of OX40L expression on the cell surface of the cell expressing OX40L is greater than 90%.

[0014] As certain embodiments of the present invention, the cell expressing OX40L is a K562 cell expressing OX40L, K562-OX40L.

[0015] The present invention also provides the use of the system, the kit, OX40L and / or cells expressing OX40L in promoting the expansion of human NK cells.

[0016] As certain embodiments of the present invention, the amino acid sequence of OX40L is as shown in SEQ ID No. 1; and the positive rate of OX40L expression on the cell surface of the cells expressing OX40L is greater than 90%.

[0017] As certain embodiments of the present invention, the cell expressing OX40L is a K562 cell expressing OX40L, K562-OX40L.

[0018] The present invention also provides a method for efficiently expanding NK cells, wherein the method comprises co-culturing OX40L and / or cells expressing OX40L with NK cells.

[0019] As certain embodiments of the present invention, the amino acid sequence of OX40L is shown in SEQ ID No. 1; the positive rate of OX40L expression on the cell surface of the cell expressing OX40L is greater than 90%.

[0020] As certain embodiments of the present invention, the cell expressing OX40L is a K562 cell expressing OX40L, K562-OX40L.

[0021] As certain embodiments of the present invention, the ratio of cells expressing OX40L to NK cells is 2-0.5:1.

[0022] The present invention also provides K562 cells K562-OX40L expressing OX40L, wherein the positive rate of OX40L expressed on the surface of the K562-OX40L cells is greater than 90%.

[0023] The present invention also provides the system, the kit, the method, or the NK cells prepared by the K562-OX40L cells.

[0024] The present invention also provides the use of the NK cells in the preparation of tumor immunotherapy drugs.

[0025] Tumor immunotherapy is a treatment method that controls and eliminates tumors by restarting and maintaining the tumor-immune cycle and restoring the body's normal anti-tumor immune response. It includes monoclonal antibody immune checkpoint inhibitors, therapeutic antibodies, cancer vaccines, cell therapy, and small molecule inhibitors.

[0026] As described above, the system, kit, and method for amplifying NK cells, the cells K562-OX40L used for amplification, the application, the prepared NK cells, and the application of NK cells of the present invention have the following beneficial effects:

[0027] The inventors overexpressed OX40L in K562 cells (expression positive rate on the cell surface> 90%) by bioengineering methods, constructed an engineered cell line of K562-OX40L, and tested the ability of K562-OX40L engineered cells in the expansion and activation of NK cells, and developed an expansion method using OX40L as a new costimulatory factor to promote the expansion of human NK cells. Compared with a control group using only K562 cells as feeder cells, the expansion method of the present invention increases the expansion efficiency by 5-10 times.

[0028] The cell line K562-OX40L developed by the inventors has the efficiency and ability to amplify NK cells.

[0029] The NK cells prepared by the amplification method of the present invention have ADCC toxicity comparable to that of NK cells amplified by using K562 cells as feeder cells, and the abundance of molecular markers expressed on the cell surface of the amplified NK cells is much higher than that of natural NK cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 The flow cytometry analysis of the present invention shows the expression of OX40L on the surface of genetically engineered K562 cells;

[0031] Figure 2 The K562-OX40L cell line of the present invention was co-cultured with PBMC cells for 4 weeks, and the expansion purity and expansion efficiency of NK cells in PBMC were detected;

[0032] Figure 3 Shown are the direct killing activity and ADCC killing activity of NK cells obtained by K562-OX40L amplification of the present invention:

[0033] Figure 4 : It shows the expression of molecular markers on the surface of NK cells obtained by amplifying K562-OX40L of the present invention. DETAILED DESCRIPTION

[0034] The present invention is further described below in conjunction with specific examples, and it should be understood that these examples are only used to illustrate the present invention and are not used to limit the scope of protection of the present invention. Those skilled in the art can easily understand other advantages and effects of the present invention from the content disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.

[0035] It should be understood that the terms used in the examples of the present invention are intended to describe specific embodiments rather than to limit the scope of protection of the present invention; in the present specification and claims, unless otherwise expressly stated, the singular forms "a", "an" and "the" include plural forms. When the examples give numerical ranges, it should be understood that unless otherwise specified in the present invention, both endpoints of each numerical range and any value between the two endpoints can be selected.

[0036] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meanings as those commonly understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, any methods, equipment, and materials of the prior art that are similar or equivalent to the methods, equipment, and materials in the embodiments of the present invention may be used to implement the present invention, based on the prior art mastery of those skilled in the art and the description of the present invention.

[0037] Unless otherwise stated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional techniques in the field of molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology, and related fields. These techniques are well described in the literature, see Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, Second edition, Cold Spring Harbor Laboratory Press, 1989 and Third edition, 2001; Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, 1987 and periodic updates; these series METHODS IN ENZYMOLOGY, Academic Press, San Diego; Wolffe, CHROMATINSTRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998; METHODS IN ENZYMOLOGY, Vol. 304, Chromatin (PM Wassarman and AP Wolffe, eds.), Academic Press, San Diego, 1999; and METHODS IN MOLECULAR BIOLOGY, Vol. 304, Chromatin (PM Wassarman and AP Wolffe, eds.), Academic Press, San Diego, 1999. BIOLOGY, Vol. 119, Chromatin Protocols (PB Becker, ed.) Humana Press, Totowa, 1999, etc.

[0038] Example 1 Preparation of K562 cell line stably expressing OX40L

[0039] 1.1 Construction, packaging and collection of OX40L lentiviral expression plasmid

[0040] The nucleic acid and amino acid sequences of OX40L were obtained from the NCBI database, and the OX40L molecules were synthesized separately by the whole gene synthesis method. Then, the obtained OX40L molecules were constructed into the pLVTHM plasmid by double enzyme digestion method, and 293 cells were used for virus packaging and collection to obtain the pLVTHM-OX40L virus supernatant, which was filtered and set aside.

[0041] The amino acid sequence of OX40L is shown in SEQ ID No. 1:

[0042] LLGLGLSTVTGLHCVGDTYPSNDRCCHECRPGNGMVSRCSRSQNTVCRPCGPGFYNDVVSSKPCKPCTWCNLRSGSERKQLCTATQDTVCRCRAGTQPLDSYKPGVDCAPCPPGHFSPGDNQACKPWTNC TLAGKHTLQPASNSSDAICEDRDPPATQPQETQGPPARPITVQPTEAWPRTSQGPSTRPVEVPGGRAVAAILGLGLVLGLLGPLAILLALYLLRRDQRLPPDAHKPPGGGSFRTPIQEEQADAHSTLAKI

[0043] 1.2 Transfection, culture and identification of K562 cells expressing OX40L

[0044] In 2×10 5 Add polybrene to 6μg / ml and appropriate amount of virus prepared in 1.1 to K562 suspension cells, mix thoroughly. Incubate at 37℃. Or centrifuge at 150g for 4 hours at room temperature (optional, this step can improve transfection efficiency for some difficult-to-transfect cell lines). After 4 hours, add an equal volume of fresh culture medium to dilute polybrene.

[0045] The cells were cultured for 3-4 days, and the cells were subcultured or the medium was changed depending on the cell growth. After 3-4 days, the cells were harvested to obtain K562 cell lines stably expressing OX40L.

[0046] Flow cytometry was used to analyze the expression of OX40L on the surface of K562 cells. Figure 1 As shown, the positive rate of OX40L expression on the surface of K562 cells was over 90%.

[0047] Example 2 K562-OX40L feeder cells enhance the expansion of NK cells in PBMCs

[0048] After K562 cells and K562-OX40L were co-cultured with PBMCs isolated from peripheral blood for 1-4 weeks, the purity of NK cells in PBMCs was determined by detecting CD3-, CD16+, and CD56+ using flow cytometry.

[0049] The purity and expansion fold of NK cells after culture with K562 or K562-OX40L feeder cells were compared. When grown with K562-OX40L feeder cells after 2 weeks of culture, an increase in the purity of expanded NK cells was observed, while the purity of NK cells co-cultured with K562 was lower than that of NK cells cultured with K562-OX40L feeder cells ( Figure 2 A).

[0050] The NK cells co-cultured with K562-OX40L feeder cells had a significantly higher expansion rate than the NK cells co-cultured with K562 feeder cells at around 28 days of culture ( Figure 2 B), the amplification efficiency of the K562-OX40L group is 5-10 times that of the K562 group.

[0051] At the same time, the WST-1 cell proliferation and cytotoxicity detection kit was used to detect the direct cell killing activity of NK cells expanded from K562 or K562-OX40L cells against Her2-positive human breast cancer cell line (MCF-7 effector cells (E)) and the ADCC killing activity mediated by Herceptin her2 antibody ( Figure 3 A and 3B). The NK cells expanded by K562 or K562-OX40L cells with different E:T ratios (2:1, 1:1, and 0.5:1, respectively) showed that the cytotoxic activity of NK cells expanded by K562-OX40L cells against MCF7 was similar to that of NK cells expanded by K562 group, indicating that the activity of NK cells obtained by K562-OX40L was similar to that of NK cells expanded by traditional methods.

[0052] Flow cytometry was also used to analyze the differences in various surface receptors (CD16, NKG2A, NKG2C, CD57, CD8a, NKp30, NKp46, CD62L, NKG2D, and DNAM-1) of NK cells expanded with K562 or K562-OX40L feeder cells on days 7 and 14. Figure 4 ), the study found that the NK cells obtained by using K562-OX40L expansion were consistent with the characteristic molecular markers on the surface of naturally derived NK cells.

[0053] The above is only a preferred embodiment of the present invention, and is not any formal or substantial limitation of the present invention. It should be pointed out that ordinary technicians in this technical field can make several improvements and supplements without departing from the method of the present invention, and these improvements and supplements should also be regarded as the protection scope of the present invention. Any technician familiar with this profession, without departing from the spirit and scope of the present invention, can make some changes, modifications and evolutions of the technical content disclosed above, which are equivalent embodiments of the present invention; at the same time, any changes, modifications and evolutions of any equivalent changes made to the above embodiments based on the essential technology of the present invention are still within the scope of the technical solution of the present invention.

Claims

1. A system for expanding NK cells, characterized in that: The system comprises OX40L and / or cells expressing OX40L; optionally, NK cells co-cultured with OX40L and / or cells expressing OX40L.

2. The system according to claim 1, characterized in that The amino acid sequence of OX40L is shown in SEQ ID No. 1; The positive rate of OX40L expression on the cell surface of the cells expressing OX40L is greater than 90%; Preferably, the cell expressing OX40L is a K562 cell expressing OX40L, K562-OX40L.

3. A kit for amplifying NK cells, characterized in that: The kit includes OX40L, and / or cells expressing OX40L.

4. The kit according to claim 3, characterized in that The amino acid sequence of OX40L is shown in SEQ ID No. 1; The positive rate of OX40L expression on the cell surface of the cells expressing OX40L is greater than 90%; Preferably, the cell expressing OX40L is a K562 cell expressing OX40L, K562-OX40L.

5. Use of the system according to any one of claims 1 to 2, the kit according to any one of claims 3 to 4, OX40L and / or cells expressing OX40L in promoting the expansion of human NK cells; The amino acid sequence of OX40L is shown in SEQ ID No. 1; The positive rate of OX40L expression on the cell surface of the cells expressing OX40L is greater than 90%; Preferably, the cell expressing OX40L is a K562 cell expressing OX40L, K562-OX40L.

6. A method for efficiently expanding NK cells, characterized in that: The method comprises co-culturing OX40L and / or cells expressing OX40L with NK cells.

7. The method according to claim 6, characterized in that The amino acid sequence of OX40L is shown in SEQ ID No. 1; The positive rate of OX40L expression on the cell surface of the cells expressing OX40L is greater than 90%; Preferably, the cell expressing OX40L is a K562 cell expressing OX40L, K562-OX40L.

8. K562 cells K562-OX40L expressing OX40L, wherein the positive rate of OX40L expressed on the surface of the K562-OX40L cells is greater than 90%.

9. NK cells prepared by the system use according to any one of claims 1 to 2, or the kit according to any one of claims 3 to 4, or the method according to any one of claims 6 to 7, or the K562-OX40L cells according to claim 8.

10. Use of the NK cells according to claim 10 in preparing tumor immunotherapy drugs.